Lower radiation dose for early-stage nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether people with early-stage nasopharyngeal cancer can receive a lower dose of radiation after chemotherapy, which may reduce side effects while still treating the cancer effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a type of nasopharyngeal cancer called non-keratinizing carcinoma (types II or III).
- Your cancer is early-stage (stage I or II) and has not spread to distant parts of the body.
- You have not had chemotherapy, targeted therapy, immunotherapy, or radiation for head and neck cancer before.
- You are generally healthy, with adequate organ function (kidney, liver, blood counts).
- You agree to have blood tests for EBV-DNA before and during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a personalized radiation plan for the neck can prevent cancer from spreading in people with nasopharyngeal carcinoma. It's for those whose cancer hasn't spread beyond the head and neck area.
This trial compares a lower dose of radiation to the standard dose for people with advanced nasopharyngeal cancer that shrank after chemotherapy and immunotherapy. The goal is to see if a lower dose works just as well with fewer side effects.
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
This trial tests a shorter course of radiation therapy for people with nasopharyngeal cancer, a type of head and neck cancer. The goal is to see if a hypofractionated (fewer, larger doses) approach is safe and effective.
This trial compares a lower dose of radiation to the standard dose for people with early-stage nasopharyngeal cancer. It aims to see if a lower dose is just as effective while reducing side effects.
This trial compares a lower dose of radiation (40.2 Gy) to the standard dose (49.2 Gy) for patients with stage II nasopharyngeal carcinoma that has shrunk after initial chemoimmunotherapy. The goal is to see if the lower dose works just as well while potentially causing fewer side effects.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.